Zusammenfassung
Neuroanatomische Studien, die mit entsprechenden Tierexperimenten gekoppelt waren, sowie Untersuchungen und Beobachtungen über die Auswirkungen von Gehirnverletzungen, elektrischen Reizungen und neurochirurgischen Eingriffen führten zu einer Kartierung der Funktionen im menschlichen Gehirn. Man geht heute davon aus, daß das Gehirn sowohl fokal (also mit klar abgegrenzten Zentren) als auch diffus organisiert ist — je nachdem, welche Funktionen man untersucht (zur Übersicht: McGeer et al. 1987). Sensorische und motorische Grundfunktionen werden von sehr spezifischen Regionen kontrolliert, während die höheren geistigen Funktionen mehrere über das Gehirn verteilte Bereiche beanspruchen. Auf zellulärer und molekularer Ebene erfolgt die Informationsübertragung über ein neuronales Netzwerk mit verschiedenen Neurotransmittersystemen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366–375
Albin RL, Young AB, Penney JB (1990) Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington’s disease. N Engl J Med 332:1293–1298
Alexander GE, Crutcher MD (1990) Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 13:266–271
Andersen PH, Jansen JA (1990) Dopamine receptor agonists: selectivity and dopamine Di receptor efficacy. Eur J Pharmacol 188:335–347
Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 20:415–455
Birkmayer W (1969) Der Alpha-Methyl-P-Tyrosin-Effekt bei extrapyramidalen Erkrankungen. Wien Klin Wochenschr 81:10–12
Burns RS, Chiueh CC, Markey SP, Eberth MH, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-l,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80:4546–4550
Carlsson A, Lindquist M, Magnusson T (1957) 2,3-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200
Carpenter MB, Carpenter CS (1951) Analysis of somatotopic relations of the corpus Luysii in man and monkey. Relation between the site of dyskinesia and distribution of lesions within the subthalamic nucleus. J Comp Neurol 95:349–351
Chevalier G, Vacher S, Deniau JM, Desban M (1985) Disinhibition as a basic process in the expression of striatal function. I. The striato-nigral influence on tecto-spinal/tecto-diencephalic neurones. Brain Res 334:215–226
Crossman AR (1987) Primate models of dyskinesias: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience 21:1–40
Crossman AR, Sambrook MA, Jackson AJ (1984) Experimental hemichorea/hemiballism in monkey. Brain 107:579–596
Crossman AR, Mitchell IJ, Jackson AJ, Sambrook MA (1988) Chorea and myoclonus in the monkey induced by gamma-aminobutyric acid antagonism in the lentiform complex: the site of drug action and a hypothesis of the neural mechanisms of chorea. Brain 111:1211–1233
Crout JR (1961) The inhibition of catechol-O-methyltransferase by pyrogallol in the rat. Biochem Pharmacol 6:47–54
Dawborn D, de Quidt ME, Emson PC (1985) Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington’s disease. Brain Res 411:251–260
DeLong MR, Alexander GE, Georgopoulos AP, Crutcher MD, Mitchel SJ, Richardson RT (1984) Role of basal ganglia in limb movements. Human Neurobiol 2:235–244
Deniau JM, Chevalier G (1985) Disinhibition as a basic process in the expression of striatal functions. II. The striato-nigral influence on thalamocortical cells of ventromedial thalamic nucleus. Brain Res 334:227–233
Ferrante RJ, Kowall NW, Beal MF, Richardson EP jr, Bird ED, Martin JB (1985) Selective sparing of a class of striatal neurons in Huntington’s disease. Science 230:561–563
Filion M, Tremblay L, Bedard PJ (1988) Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys. Brain Res 444:165–176
Fonnum F (1984) Glutamate: a neurotransmitter in mammalian brain. J Neurochem 42:1–11
Fonnum F, Soreide A, Kvale I, Walker J, Walaas I (1981) Glutamate in cortical fibres. In: DiChiara G, Gessa GL (eds) Glutamate as a neurotransmitter. Raven Press, New York, pp 29–41
Gibb WRG, Terruli M, Lees AJ, Jenner P, Marsden CD (1989) The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Mov Disord 4:53–74
Graybiel AM (1990) Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 13:244–254
Graybiel AM, Ragsdale CW (1983) Biochemical anatomy of the striatum. In: Emson PC (ed) Chemical neuroanatomy. Raven Press, New York, pp 427–504
Heidmann T, Changeux JP (1978) Structural and functional properties of the acetylcholine receptor protein in its purified and membrane-bound states. Ann Rev Biochem 47:317–357
Hucho F (Hrsg) (1982) Einführung in die Neurochemie. Verlag Chemie, Weinheim
Hunt P, Kannengiesser MH, Raynaud JP (1974) Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatum. J Pharm Pharmacol 26:370–371
Jakob H, Beckmann H (1986) Prenatal development disturbances in the limbic allocortex in schizophrenics. J Neural Transm 65:303–326
Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17:1285–1297
Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmüller B (1980) Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20:379–382
Kinemuchi H, Fowler C, Tipton KF (1987) The neurotoxicity of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) and its relevance to Parkinson’s disease. Neurochem Int 11:359–373
Kitai ST, Kita H (1987) Anatomy and physiology of the subthalamic nucleus: a driving force of the basal ganglia. In: Carpenter MM, Jayaraman A (eds) The basal ganglia II, structure and function: current concepts. Plenum Press, New York (Advances in behavioral biology, Vol 31, pp 357–373)
Knoll J (1986) The pharmacology of (-)-deprenyl. J Neural Transm [Suppl] 22:75–89
Kornhuber HH, Kornhuber J, Kim JS, Kornhuber ME (1984) Zur biochemischen Theorie der Schizophrenie. Nervenarzt 55:602–606
Kornhuber J, Mack-Burkhardt F, Riederer P, Hebenstreit GF, Reynolds GP, Andrews HB, Beckmann H (1989) [3H] MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 77:231–236
Lundberg JM, Hökfelt T (1983) Coexistence of peptides and classical transmitters. Trends Neurosci 6:325–333
Martin JB, Gusella JF (1986) Huntington’s disease: pathogenesis and management. N End J Med 315:1267–1276
McGeer PL, Sir Eccles JC, McGeer EG (eds) (1987) Molecular neurobiology of the mammalian brain, 2nd edn. Plenum Press, New York
Miller WC, DeLong MR (1987) Altered tonic activity of neurones in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In: Carpenter MB, Jayaraman A (eds) The basal ganglia II, structure and function: current concepts. Plenum Press, New York (Advances in behavioral biology, Vol 32, pp 395-403)
Mitchell IJ, Clarke CE, Boyce S, Robertson RG, Peggs D, Sambrook MA, Crossman AR (1989) Neural mechamisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine. Neuroscience 32:213–226
Mitchell PR, Doggett NS (1980) Modulation of striatal 3H-glutamic acid release by dopaminergic drugs. Life Sci 26:2073–2081
Mitchell R (1987) Molecular aspects of central neurotransmitter function. In: Flückinger E, Müller E, Thorner MO (eds) Basic and clinical aspects of neuroscience, Vol 2. Springer, Berlin Heidelberg New York Tokyo, pp 1–9
Nagatsu T, Levitt M, Udenfriend S (1964) Tyrosine hydroxylase, the initial step in norepinephrine biosynthesis. J Biol Chem 239:2910–2917
Nauta WJH, Domesick VB (1984) Afferent and efferent relationships of the basal ganglia. In: Evered D, O’Connor M (eds) Functions of the basal ganglia. Pitman, London, pp 3–23
Nicoll RA, Malenka RC, Kauer JA (1990) Functional comparison of neurotransmitter receptor subtypes in mammalian central nervous system. Physiol Rev 70:513–565
Nieoullon A, Kerkerian L, Dusticier N (1982) Inhibitory effects of dopamine on high affinity glutamate uptake from rat striatum. Life Sci 30:1165–1172
Penney JB, Young AB (1981) GAB A as the pallidothalamic neurotransmitter: implications for basal ganglia function. Brain Res 207:195–199
Peroutka SJ (1988) 5-Hydroxytryptamine receptor subtypes. Annu Rev Neurosci 11:45–60
Phelps PA, Houser CR, Vaughn JE (1985) Immunocytochemical localizaton of choline acetyltransferase within the rat neostriatum: a correlated light and electron microscopic study of cholinergic neurons and synapses. J Comp Neurol 238:286–307
Reiner A, Albin RL, Anderson KD, D’Amato CJ, Penney JB, Young AB (1988) Differential loss of striatal projection neurons in Huntington’s disease. Proc Natl Acad Sci USA 85:5733–5737
Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in Parkinson’s disease. J Neural Transm 39:277–301
Roos RAC (1986) Neuropathology of Huntington’s chorea. In: Vinken PJ, Bruyn GW, Klawans HL (eds) Extrapyramidal disorders. Elsevier, New York (Handbook of clinical neurology, Vol 49, pp 315-326)
Russ H, Mihatsch W, Gerlach M, Riederer P, Przuntek H (1991) Neurochemical and behavioural features induced by chronic low dose treatment with l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson’s disease. Neurosci Lett 123:115–118
Schwartz WJ, Smith CB, Davidsen L, Savaki H, Sokoloff L (1979) Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. Science 205:723–725
Smith Y, Parent A (1988) Neurons of the subthalamic nucleus in primates display glutamate but not GABA immunoreactivity. Brain Res 453:353–356
Wagner GC, Seiden LS, Schuster CR (1979) Methamphetamine-induced changes in brain catecholamines in rats and guinea pigs. Drug Alcohol Dep 4:435–438
Walker FO, Young AB, Penney JB, Dorovini-Zis K, Shoulson I (1984) Benzodiazepine and GABA receptors in early Huntington’s disease. Neurology 34:1237–1240
Young AB, Penney JB (1988) Biochemical and functional organization of the basal ganglia. In: Jankovic J, Tolosa E (eds) Parkinsons’s disease and movement disorders. Urban & Schwarzenberg, München, pp 1–11
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Gerlach, M., Gsell, W., Riederer, P. (1991). Anatomische, biochemische und funktionelle Strukturen physiologischer Neurotransmitter-Regelkreise. In: Beckmann, H., Osterheider, M. (eds) Neurotransmitter und psychische Erkrankungen. Tropon-Symposium VI, vol 6. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84544-4_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-84544-4_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-54220-9
Online ISBN: 978-3-642-84544-4
eBook Packages: Springer Book Archive